JSB Market Research: Nuclear Medicine Market and Radiopharmaceuticals - Global Trends & Forecast to 2017
The market of radiopharmaceuticals is dominated by diagnostic radioisotopes, comprising of SPECT and PET radioisotopes. The lions share of the SPECT market is taken up by Tc-99m, whereas the PET market is dominated by F-18FDG isotope.
The market of radiopharmaceuticals is dominated by diagnostic radioisotopes, comprising of SPECT and PET radioisotopes. The lions share of the SPECT market is taken up by Tc-99m, whereas the PET market is dominated by F-18FDG isotope.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
4.1 Introduction<br />
4.2 Diagnostic <strong>Market</strong><br />
4.2.1 Opportunity Matrix<br />
4.2.2 Spect <strong>Radiopharmaceuticals</strong><br />
4.2.2.1 Technetium-99m (TC-99m)<br />
4.2.2.1.1 Tc-99m To Decide Growth Trend Of Spect Radioiso<strong>to</strong>pes<br />
4.2.2.1.2 Fac<strong>to</strong>rs Affecting Technetium-99m <strong>Market</strong><br />
4.2.2.1.2.1 Technetium Can Combine With 31 Different Carrier Molecules<br />
4.2.2.1.2.2 Lack Of Availability Of Technetium<br />
4.2.2.2 Thallium-201 (TL-201)<br />
4.2.2.2.1 Tl-201 Is A Potential Substitute For TC-99m<br />
4.2.2.3 Gallium-67 (GA-67)<br />
4.2.2.3.1 Fluorine-18 Might Seize Ga-67 <strong>Market</strong> Share In The Near Future<br />
4.2.2.4 Iodine (I-123)<br />
4.2.2.5 Others<br />
4.2.3 Pet <strong>Radiopharmaceuticals</strong><br />
4.2.3.1 Fluorine-18<br />
4.2.3.1.1 Fdg<br />
4.2.3.1.2 Florbetapir<br />
4.2.3.1.3 Fac<strong>to</strong>rs Affecting Fluorine-18 <strong>Market</strong><br />
4.2.3.1.3.1 Increasing Availability Of Pet Machines<br />
4.2.3.1.3.2 Rise In Pet Procedures Increases Dem<strong>and</strong> For Fdg<br />
4.2.3.1.3.3 High Generation Costs Of Fdg<br />
4.2.3.1.3.4 Need For Speedy & Efficient Transportation<br />
4.2.3.2 Rubidium-82 (RB-82)<br />
4.2.3.2.1 Bracco Re-Launched Cardiogen-82 In Feb-12<br />
4.2.3.3 Others<br />
4.2.3.3.1 Ga-68 Deemed As A Potential Pet Radioiso<strong>to</strong>pe<br />
4.3 Therapeutic <strong>Market</strong><br />
4.3.1 Opportunity Matrix<br />
4.3.2 Beta Emitters<br />
4.3.2.1 Iodine-131 (I-131)<br />
4.3.2.2 Yttrium-90 (Y-90)<br />
4.3.2.2.1 Y-90 <strong>Market</strong> Influenced By Popularity Of Nordion’s Therasphere<br />
4.3.2.3 Samarium-153 (SM-153)<br />
4.3.2.4 Rhenium-186 (RE-186)<br />
4.3.2.5 Lutetium-177 (LU-177)<br />
4.3.2.5.1 LU-177 Is A Potential Treatment Option For Neuroendocrine Cancer<br />
4.3.2.6 Others<br />
4.3.2.6.1 Re-188 And P-33 Are Notable Promising Iso<strong>to</strong>pe<br />
4.3.3 Alpha Emitters<br />
4.3.3.1 Radium-223 (RA-223) & Alpharadin<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
Change language